iOmx Therapeutics Initiates Phase Ib with OMX-0407
22 août 2024 04h00 HE
|
iOmx Therapeutics AG
Data from the successful Phase Ia dose escalation study showed that OMX-0407 monotherapy demonstrated a favorable safety profile and signs of anti-tumor activity, with one durable complete response in...